125
Views
14
CrossRef citations to date
0
Altmetric
Original Research

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

, , &
Pages 105-117 | Published online: 09 Feb 2015

References

  • BoyleITBones for the futureActa Paediatr Scand Suppl19918037358651927530
  • McClungMRThe menopause and HRT. Prevention and management of osteoporosisBest Pract Res Clin Endocrinol Metab2003171537112763512
  • McNamaraLMPerspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fracturesJ R Soc Interface201074435337219846441
  • BianchiMLOrsiniMRSaraifogerSOrtolaniSRadaelliGBettiSQuality of life in post-menopausal osteoporosisHealth Qual Life Outcomes200537816321148
  • MarquisPCialdellaPDe la LogeCDevelopment and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOSTQual Life Res200110655556611789555
  • CalvoEMorcilloDForuriaAMRedondo-SantamariaEOsorio-PicorneFCaeiroJRGEIOS-SECOT Outpatient Osteoporotic Fracture Study GroupNondisplaced proximal humeral fractures: high incidence among outpatient-treated osteoporotic fractures and severe impact on upper extremity function and patient subjective health perceptionJ Shoulder Elbow Surg201120579580121195633
  • Sanfelix-GenovesJHurtadoISanfelix-GimenoGReig-MollaBPeiroSImpact of osteoporosis and vertebral fractures on quality-of-life. A population-based study in Valencia, Spain (the FRAVO study)Health Qual Life Outcomes201192021470396
  • AdkinsJKassianosGIbandronate – a convenient and effective treatment option for the management of post-menopausal osteoporosisDrugs Context200842121134
  • AkaNBalkanEZeynep Tuzcular VuralEYaziciogluEThe risk factors in postmenopausal osteoporosisMarmara Medical Journal2000134219222
  • Diaz CurielMGarciaJJCarrascoJLPrevalence of osteoporosis assessed by densitometry in the Spanish female populationMed Clin (Barc)200111638688 Spanish11181284
  • CiprianiCRomagnoliEMinisolaSPharmacological treatment of osteoporosis – old and new drugsEur Musculoskelet Rev2011628387
  • ColeZDennisonECooperCUpdate on the treatment of post-menopausal osteoporosisBr Med Bull200886112914318477578
  • SammartinoACirilloDMandatoVDDi CarloCNappiCOsteoporosis and cardiovascular disease: benefit-risk of hormone replacement therapyJ Endocrinol Invest20052810 Suppl808416550729
  • Viktoria SteinKDornerTLawrenceKKunzeMRiederAEconomic concepts for measuring the costs of illness of osteoporosis: an international comparisonWien Med Wochenschr20091599–10253261 German19484209
  • BouzaCLopezTPalmaMAmateJMHospitalised osteoporotic vertebral fractures in Spain: analysis of the National Hospital Discharge RegistryOsteoporos Int200718564965717221295
  • PueyoMJLarrosaMSurisXGarcia-RuizAJCost-utility and budget impact analysis of primary prevention with alendronate of osteoporotic hip fractures in CataloniaReumatol Clin20128312813422421456
  • RizzoliRBisphosphonates for post-menopausal osteoporosis: are they all the same?QJM2011104428130021258058
  • CavalliLBrandiMLTargeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utilityTher Clin Risk Manag2012825326622745560
  • AdamiSFelsenbergDChristiansenCEfficacy and safety of ibandronate given by intravenous injection once every 3 monthsBone200434588188915121020
  • KremerRNew targets for osteoporosisPresented at the International Symposium on Multidisciplinary Approaches to Modern Therapeutics Joining Forces for a Healthier TomorrowMay 24–27, 2011Montreal, QC, Canada
  • BoyleWJSimonetWSLaceyDLOsteoclast differentiation and activationNature2003423693733734212748652
  • PolaEColangeloDFuscoAEfficacy of the anabolic therapies in severe osteoporosis: experience of a team of endocrinologists and orthopaedic surgeons and clinical resultsJ Orthopaed Traumatol201112Suppl 1S1S22
  • PrzedlackiJStrontium ranelate in post-menopausal osteoporosisEndokrynol Pol2011621657221365582
  • CorradoAQuartaLErricoSCantatoreFPSuccessful treatment of avascular bone necrosis of the knee with neridronate: a case reportRheumatol Int200727989189317285278
  • CotteFECortetBLafumaAA model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in FranceJoint Bone Spine200875220120817988921
  • CotteFEDe PouvourvilleGCost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in FranceBMC Health Serv Res20111115121702989
  • PayerJCiernyDKillingerZSulkovaIBehuliakMCelecPPreferences of patients with post-menopausal osteoporosis treated with bisphosphonates – the VIVA II studyJ Int Med Res20093741225122919761708
  • Sicras-MainarANavarro-ArtiedaRGutierrezLSorioFIntorciaMPersistence to postmenopausal osteoporosis (PMO) treatments in a region of SpainValue Health2010137A380
  • KaramustafaFCelebiNBisphosphonates and alendronateFABAD J Pharm Sci20063113142
  • PerazellaMAMarkowitzGSBisphosphonate nephrotoxicityKidney Int200874111385139318685574
  • BorromeoGLBrandCClementJGIs bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled studyBMC Musculoskelet Disord2011127121477374
  • Perez EdoLAlonso RuizARoig VilasecaDUpdate of the consensus statement of the Spanish Society of Rheumatology on osteoporosisReumatol Clin201176357379 Spanish22078694
  • JonssonBStromOEismanJACost-effectiveness of denosumab for the treatment of postmenopausal osteoporosisOsteoporos Int201122396798220936401
  • StromOBorgstromFSenSSCost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries – an economic evaluation based on the Fracture Intervention TrialOsteoporos Int20071881047106117333449
  • KanisJAJohnellOOdenAJonssonBDawsonADereWRisk of hip fracture derived from relative risks: an analysis applied to the population of SwedenOsteoporos Int200011212012710793869
  • De LaetCEvan HoutBABurgerHHofmanAPolsHABone density and risk of hip fracture in men and women: cross sectional analysisBMJ199731571022212259253270
  • JohnellOKanisJAOdenAPredictive value of BMD for hip and other fracturesJ Bone Miner Res20052071185119415940371
  • KlotzbuecherCMRossPDLandsmanPBAbbottTA3rdBergerMPatients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesisJ Bone Miner Res200015472173910780864
  • SimonJARecknorCMoffettAHJrImpact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fractureMenopause201320213013723010883
  • CummingsSRSan MartinJMcClungMRDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
  • National Collaborating Centre for Nursing and Supportive CareSystematic reviews of clinical effectiveness prepared for the guideline ‘Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk’London, UKNational Institute for Health and Clinical Excellence2008 Available from: https://www.nice.org.uk/guidance/cg146/documents/osteoporosis-evidence-reviews2Accessed January 16, 2015
  • BoonenSAdachiJDManZTreatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high riskJ Clin Endocrinol Metab20119661727173621411557
  • McClungMBoonenSTorringOEffect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosisJ Bone Miner Res201227121121821976367
  • HemminkiADmitrievILiuBDesmondRAAlemanyRCurielDTTargeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion moleculeCancer Res200161176377638111522629
  • HiligsmannMBoonenADirksenCDBen SedrineWReginsterJYCost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic womenExpert Rev Pharmacoecon Outcomes Res2013131192823402442
  • HiligsmannMReginsterJYCost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in BelgiumPharmacoeconomics2011291089591121692551
  • Alvarez-NebredaMLJimenezABRodriguezPSerraJAEpidemiology of hip fracture in the elderly in SpainBone200842227828518037366
  • IsmailAAPyeSRCockerillWCIncidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS)Osteoporos Int200213756557112111017
  • MarinFGonzalez-MaciasJMoyaRFragility non-spinal fractures in a cohort of 5,201 women aged 65 years and older during a 3-year follow-upMed Clin (Barc)200612711401404 Spanish17020682
  • Naves DiazMDiaz LopezJBGomez AlonsoCAltadill ArreguiARodriguez RebollarACannata AndiaJBStudy of incidence of osteoporotic fractures in a cohort of individuals older than 50 years from Asturias, Spain, after a 6 year follow-up periodMed Clin (Barc)200011517650653 Spanish11141414
  • EPOS Study GroupIncidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS)J Bone Miner Res200217471672411918229
  • KanisJAOdenAJohnellODe LaetCJonssonBExcess mortality after hospitalisation for vertebral fractureOsteoporos Int200415210811214598026
  • KanisJAOdenAJohnellODe LaetCJonssonBOglesbyAKThe components of excess mortality after hip fractureBone200332546847312753862
  • Instituto Nacional de EstadisticaPopulation figures and demographic censuses2011 Available from: http://www.ine.es/inebmenu/mnu_cifraspob.htm#6Accessed January 16, 2015 Spanish
  • BarrettJABaronJABeachMLMortality and pulmonary embolism after fracture in the elderlyOsteoporos Int2003141188989412942231
  • ParkerMJAnandJKWhat is the true mortality of hip fractures?Public Health199110564434461803403
  • GisbertRBrosaMSpanish Health Costs Database 2011 Available from http://www.oblikue.com/bddcostes/Accessed January 16, 2015
  • Consejo General de Colegios Oficiales de FarmacéuticosPortalfarma2014 Available from http://www.portalfarma.com/inicio/botplus20/Paginas/Bot-PLUS-2-0.aspxAccessed January 16, 2015
  • BaztanJJCaceresLALlanqueJLGavidiaJJRuiperezIPredictors of functional recovery in older hospitalized adultsJ Am Geriatr Soc201260118718922239317
  • De la Torre GarcíaMRodríguez PérezJCMoreno MoreuNJacintoRLHernández SantanaADeive MaggioloJCEconomic impact study of the hip fractures in our midstTrauma2012231 Spanish
  • Lopez-BastidaJOlivaJAntonanzasFSpanish recommendations on economic evaluation of health technologiesEur J Health Econ201011551352020405159
  • KanisJAJohnellOOdenAThe risk and burden of vertebral fractures in SwedenOsteoporos Int2004151202614593450
  • PeasgoodTHerrmannKKanisJABrazierJEAn updated systematic review of health state utility values for osteoporosis related conditionsOsteoporos Int200920685386819271098
  • KanisJACooperCHiligsmannMRabendaVReginsterJYRizzoliRPartial adherence: a new perspective on health economic assessment in osteoporosisOsteoporos Int201122102565257321617992
  • FreemantleNSatram-HoangSTangETFinal results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal womenOsteoporos Int201223131732621927922
  • LandfeldtEStromORobbinsSBorgstromFAdherence to treatment of primary osteoporosis and its association to fractures – the Swedish Adherence Register Analysis (SARA)Osteoporos Int201223243344321286686
  • CaulinFKanisJAJohnellOOdenAOptimal age for preventing osteoporosis after menopause depends on effects of stopping treatmentBone200230575475811996915
  • JonssonBKanisJDawsonAOdenAJohnellOEffect and offset of effect of treatments for hip fracture on health outcomesOsteoporos Int199910319319910525710
  • HaradaAAbsolute risk for fracture and WHO guideline. Economic analysis of pharmacotherapy for osteoporosisClin Calcium200717710291034 Japanese17607069
  • KanisJABorgstromFZethraeusNJohnellOOdenAJonssonBIntervention thresholds for osteoporosis in the UKBone2005361223215663999
  • MullinsCDOhsfeldtRLModeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapyJ Manag Care Pharm20039215015814613344
  • StromOBorgstromFKanisJAJonssonBIncorporating adherence into health economic modelling of osteoporosisOsteoporos Int2009201233418521650
  • BorgstromFZethraeusNJohnellOCosts and quality of life associated with osteoporosis-related fractures in SwedenOsteoporos Int200617563765016283064
  • ZethraeusNStromCMBorgstromAWhat is the risk of institutionalization after hip fracture?Osteoporosis Int200617Suppl 2S60
  • Sanfelix-GenovesJReig-MollaBSanfelix-GimenoGThe population-based prevalence of osteoporotic vertebral fracture and densitometric osteoporosis in postmenopausal women over 50 in Valencia, Spain (the FRAVO study)Bone201047361061620601286
  • De CockEMiravitllesMRamón González-JuanateyJRamón Azanza-PereaJThreshold of cost per life year gained to recommend the adoption of health technologies in Spain: evidence from a review of the literaturePharmacoeconomics – Spanish Research Articles20074397107 Spanish
  • SacristanJAOlivaJDel LlanoJPrietoLPintoJLWhat is an efficient health technology in Spain?Gac Sanit2002164334343 Spanish12113733
  • OusterhoutMMBlaserDAGagnonJCost-effectiveness comparative analysis of bisphosphonates for the treatment of post-menopausal osteoporosisPresented at the 16th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes ResearchMay 21–25, 2011Baltimore, MD, USA
  • LippunerKPollockRFSmith-PalmerJMeuryTValentineWJA review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in SwitzerlandAppl Health Econ Health Policy20119640341721910511
  • MuellerDGandjourACost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosisAppl Health Econ Health Policy20119425927321682353
  • IglesiasCPTorgersonDJBearneABoseUThe cost utility of bisphosphonate treatment in established osteoporosisQJM200295530531111978902
  • MaggiSPasqualeMBouinOModeled cost-effectiveness of rise-dronate versus ibandronate: the case of ItalyJ Bone Miner Res200823SupplS213
  • BorgstromFCarlssonASintonenHThe cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspectiveOsteoporos Int2006177996100716570118
  • BorgstromFStromOKlemanMCost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspectiveOsteoporos Int201122395596520532482
  • KimKSvedbomALuoXSutradharSKanisJAComparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithmOsteoporos Int201425132533724114398
  • HartWMRubio-TerresCBurrellAAristeguiIEscobar-JimenezFPharmacoeconomic analysis of the treatment of postmenopausal osteoporosis with risedronate or alendronateRevista Espanola de Enfermedades Metabolicas Oseas200211397104 Spanish
  • AthanasakisKKarampliEHollandezosMA cost-effectiveness analysis of denosumab for the treatment of post-menopausal osteoporosis in GreeceValue Health2011147A308
  • CristinoJCanhaoHPerelmanJSantosCPereiraJCost-utility analysis of denosumab versus standard care in the treatment of post-menopausal osteoporosis in PortugalPoster presented at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes ResearchMay 21–25, 2011Baltimore, MD, USA
  • ParthanADeflinMMYurginNHuangJTaylorDCCost-effectiveness of denosumab versus oral bisphosphonates in the United States for post-menopausal osteoporosis (PMO)Abstract PMS26 presented at the 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes ResearchJune 2–6, 2012Washington, DC, USA
  • ChauDBeckerDLCoombesMEIoannidisGAdachiJDGoereeRCost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in CanadaJ Med Econ201215Suppl 131423035625
  • AnastasilakisADToulisKAPolyzosSAAnastasilakisCDMakrasPLong-term treatment of osteoporosis: safety and efficacy appraisal of denosumabTher Clin Risk Manag2012829530622767993
  • PapapoulosSLippunerKRouxCEight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extensionJ Osteoporosis Int20142524647
  • National Insitute of Health and Clinical ExcellenceAlendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended), 2011 Available from: http://www.nice.org.uk/guidance/ta161Accessed January 16, 2015
  • InderjeethCAFooACLaiMMGlendenningPEfficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidenceBone200944574475119130909
  • Imaz IglesiaIAnálisis coste-utilidad de los tratamientos farmacológicos para la prevención de fracturas en mujeres con osteoporosis en EspañaIPE 63/2010Agencia de Evaluación de Tecnologías Sanitarias. Instituto de Salud Carlos IIIMadrid2010